@article{ref1,
title="Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study",
journal="American journal of psychiatry",
year="2002",
author="Stein, Murray B. and Kline, Neal A. and Matloff, Jeffrey L.",
volume="159",
number="10",
pages="1777-1779",
abstract="OBJECTIVE: Posttraumatic stress disorder (PTSD), particularly in combat veterans with chronic illness, is often refractory to standard pharmacological interventions. There is a need to test adjunctive treatments to boost response. <br><br>METHOD: Subjects were 19 patients with PTSD who were minimally responsive to 12 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI) at maximum tolerated dose. Outcomes were compared among subjects whose treatment was augmented with 8 weeks of double-blind olanzapine or placebo administration. <br><br>RESULTS: Olanzapine augmentation was associated with statistically significantly greater reduction than placebo in specific measures of posttraumatic stress, depressive, and sleep disorder symptoms. Clinician-rated global response rates did not, however, significantly differ between groups. <br><br>CONCLUSIONS: This is most likely the first double-blind, placebo-controlled study of an adjunct to SSRIs for PTSD. Despite the small group size, the findings suggest a role for olanzapine or other atypical antipsychotics in treating SSRI-resistant PTSD. Sleep symptoms may especially benefit.<p /><p>Language: en</p>",
language="en",
issn="0002-953X",
doi="10.1176/appi.ajp.159.10.1777",
url="http://dx.doi.org/10.1176/appi.ajp.159.10.1777"
}